Ionis Pharmaceuticals Licenses Oral RNA-based Therapeutic to Janssen
The antisense drug will be the first in the companies’ joint development deal for medications to treat autoimmune disorders of the gastrointestinal tract.
Upon completion of investigational new drug studies for IONIS-JBI1-2.5RX, Janssen will take over the development of Ionis Pharmaceuticals’ antisense drug, Ionis announced on July 19, 2016 in a press release. The drug is an RNA-based therapeutic that is delivered orally and works on an “undisclosed target” in the gastrointestinal tract. The licensing action is occurring a year and a half after the companies first announced their partnership deal, and Ionis will receive $10 million from the licensing agreement, as well as a portion of sales of commercialized product.
The deal with Janssen covers three Ionis drug programs to treat autoimmune disorders of the lower digestive system. Ionis is also in partnerships with other companies to commercialize various RNA-based therapeutics, including deals with Akcea Therapeutics, GlaxoSmithKline, and Biogen.
Source: Ionis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
